Life Sciences Investor Forum
For Fiscal Year Ending Dec 31, 2019
Receive updates straight into your inbox
CNS Pharmaceuticals is a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors.
Our lead drug, Berubicin, is an exciting discovery for the treatment of Glioblastoma Multiforme (GBM) and potentially for other CNS malignancies. Berubicin was first discovered at the largest cancer institutes in the world.
CNS has obtained a worldwide exclusive license to the Berubicin patent from Houston Pharmaceuticals, the original commercial holder of the Berubicin intellectual property.
CNS has also acquired all data and know-how related to the Phase 1 trial of Berubicin from Reata Pharmaceuticals, a multibillion dollar NASDAQ listed company. In 2017, CNS entered into a collaboration agreement with Reata to further advance the development of Berubicin.
In 2020, with the funding secured from our NASDAQ IPO, CNS will commence its Phase 2(a) clinical trial of Berubicin for the treatment of GBM.
CNS may also pursue the development of Berubicin to treat additional diseases, including pancreatic and ovarian cancers and lymphoma. CNS may also develop combination therapies that include Berubicin.
CNS Pharmaceuticals, Inc.
2100 West Loop South Suite 900 Houston, TX 77027
Continental Stock Transfer & Trust Company 1 State Street 30th Floor New York, NY 10004 T: 800-509-5586 [email protected]
© 2020 CNS Pharmaceuticals. All Rights Reserved, CNS Pharma